

**ISICR Interferon Meeting**  
**September 16-19, 2007**  
**The Examination Schools, Oxford**

**FINAL PROGRAMME**

**SUNDAY 16 September**

17.00 - 18.00 Welcome reception – Cocktails on the lawn

18.00 - 18.20 Welcome address – **The President**

18.20 - 19.30 Prizes and awards

**History of interferon**

Chair: **J. Skehel**

19.30 - 19.50 **J. Lindenmann** **The Interferon**  
19.50 - 20.30 **C. Weissmann** **'Prions – novel infectious agents of increasing importance'**

20.30 Retire to colleges for dinner

**MONDAY 17 September**

08.30 - 10.30 **Plenary P1 – Interferon induction**

Chairs: **J. Hiscott/M. Gale**

08.30 – 09.00 **M. Gale** – Interferon Induction  
09.00 – 09.15 P-1-1 **Fitzgerald-Bocarsley P** - Live cell-nibbling of HSV-infected cells by plasmacytoid dendritic cells (pDC) leads to production of IFN- $\alpha$  but is subverted by HIV-infected cells  
09.15 – 09.30 P-1-2 **Kato H**, - Functional role of RIG-I family in antiviral responses  
09.30 – 09.45 P-1-3 **Mossman, K**- Membrane Fusion Mediates the IRF3-dependent IFN-independent Antiviral Response Following Virus Entry  
09.45 – 10.00 P-1-4 **Ozato, K** - Type I interferon induction in dendritic cells depends on IRF-8  
10.00 – 10.15 P-1-5 **Pitha, P** - Characterization of murine IRF-5 and its role in the innate antiviral response .  
10.15 – 10.30 P-1-6 **Young, H** - Dissecting the role of miRNAs in IFN-gamma Gene Expression  
10.30 - 11.00 **Coffee Break**

11.00 - 13.00

**Break-out sessions:**

**B1 - Receptor interaction**

**Chair:** S. Pestka/G Uze

- 11.00 - 11.30 B-1-1 **G. Uze** The type I IFN-receptor complex: Beauty and complexity
- 11.30 – 11.45 B-1-2 **Krause C** Extensions and Improvements in Measuring Interactions Between IFN Receptor Chains
- 11.45 – 12.00 B-1-3 **Langer J** Novel Type I Interferon Antagonists
- 12.00 – 12.15 B-1-4 **Rahbar R** Chemokine receptor 5 is required for vaccinia virus infection in vivo
- 12.15 – 12.30 B-1-5 **Stacheli P** Interferon-lambda contributes to influenza virus resistance of mice carrying functional Mx1 resistance gene B-1-
- 12.30 – 12.45 B-1-6 **Noppert S** Role of Type I Interferon in Lipopolysaccharide-mediated Inflammation
- 12.45 – 13.00 B-1-7 **Samarajiva SA** Soluble IFNAR2 Signaling Potentiates TLR4 Induced IFN $\alpha$  Mediated Septic Shock *In Vivo*

**B2 – Apoptosis**

**Chair:** M Clemens/H Wajant

- 11.00 – 11.30 **H. Wajant** Interferons and Apoptosis
- 11.30 – 11.45 B-2-1 **Barnes B** A critical role for IRF-5 in the cellular response to genotoxic stress
- 11.45 – 12.00 B-2-2 **Clemens M** Interferon-alpha desensitizes Jurkat cells to the inhibition of protein synthesis by TRAIL
- 12.00 – 12.15 B-2-3 **Gade P A** Critical Role For Transcription Factor C/EBP-beta In Regulating the Interferon Induced Expression of the Metastasis Regulatory Gene, Death associated Protein Kinase-1
- 12.15 – 12.30 B-2-4 **Romero AL** Integration of STAT2 and BIM Signals Regulate Type I IFN-Induced Apoptosis
- 12.30 – 12.45 B-2-5 **Sun P** Loss-of-expression of GRIM19, a Novel STAT3 Inhibitor, in the Human Renal Cell Carcinoma
- 12.45 – 13.00 B-2-6 **Brabant B** Characterization of Sepsis Induced Apoptotic Pathways

13.00 - 14.30

**LUNCH & POSTERS**

14.30 - 16.30

**Break-out Sessions:  
B3 - Non-classical effects of interferons**

**Chair: G.Lombardi/R.Flavell**

- 14.30 – 15.00 **R. Flavell** Non-classical effects of interferon
- 15.00 – 15.15 B-3-1 **Hofer M** Lethal lymphocytic choriomeningitis virus (LCMV) infection in STAT1 KO mice is associated with dysregulated PD-1/B7-H1 and a phenotypic switch in the T-cell response
- 15.15 – 15.30 B-3-2 **Larner A** A Novel Role for Mitochondrial-Localized Stat3 in Cellular Respiration
- 15.30 – 15.45 B-3-3 **Murooka T** CCL5-Mediated T Cell Chemotaxis Involves The Initiation Of Mrna Translation Through Pi-3'k/Mtor/4e-Bp1
- 15.45 – 16.00 B-3-4 **Li X** The critical role of IRAK4 kinase activity in TLR-mediated innate immunity
- 16.00 – 16.15 B-3-5 **Fujita T** Non-self RNA Sensing Mechanism of RIG-I Helicase and Activation of Antiviral Immune Responses
- 16.15 – 16.30 B-3-6 **Loo Y-M** Distinct RIG-I and MDA5 Signaling Regulation by RNA Viruses in Innate Immunity

**B4 – Interferon-inducible genes**

**Chair: L Hibbert/G Sen**

- 14.30 – 15.00 **G.Sen** Interferon inducible genes
- 15.00 – 15.15 B-4-1 **Andersen J** The ribosomal machinery is a primary target of RNase-L regulation and may mediate its roles in senescence and longevity
- 15.15 – 15.30 B-4-2 **Leaman D** Regulation of Apoptotic Responses to Virus or Double-stranded RNA by Noxa and Mcl-1: Synergistic Role of the Cellular Unfolded Protein Response
- 15.30 – 15.45 B-4-3 **Levi B-Z** The Role of IRF-8 in Innate Resistance to Intraphagosomal Pathogens through the Regulation of Nramp1 (Slc11a1)
- 15.45 – 16.00 B-4-4 **Pfeffer L** Identification Of Cxcl11 As A Stat3-Dependent Gene Induced By IFN
- 16.00 – 16.15 B-4-5 **Samuel C** Expression And Function Of The Interferon-Inducible Double- Stranded Rna A-To-I Editing Enzyme Adar1
- 16.15 – 16.30 B-4-6 **Xu D** Transcription factor Promyelocytic Leukemia Zinc Finger protein regulates the induction of subset of interferon-stimulated genes

16.30 - 16.50

**Tea Break**

16.50 - 19.25 **Plenary P2 – Signaling**

**Chair:** **G Stark/U Vinkemeier**

16.50 – 17.15 **G Stark Interferon signaling – Jaks and STATs**

17.15 – 17.40 **U Vinkemeier Interferon signalling – Other signaling pathways**

17.40 – 17.55 P-2-1 **Rani M** Requirement of JAK-STAT and accessory signals for Interferon-beta-induction of a subset of genes

17.55 – 18.10 P-2-2 **van Boxel-Dezaire A** Differential STAT activation in primary human blood cells after IFN- $\beta$  stimulation

18.10 – 18.25 P-2-3 **Fredericksen B** Establishment and maintenance of the innate antiviral response to West Nile virus involves both RIG-I and MDA5 signaling through IPS-1

18.25 – 18.40 P-2-4 **Krishnamurthy M** Small Self RNA Generated by RNase L Amplifies Antiviral Innate Immunity

18.40 – 18.55 P-2-5 **Platanias L** Interferon-dependent regulation of mRNA translation and generation of biological responses via mTOR- and RSK-dependent signaling cascades.

18.55 – 19.10 P-2-6 **Reich N** Cellular Dynamics Of Latent and Activated STAT5a

19.10 – 19.25 P-2-7 **Zoon K** Hu Interfeon-alphas: Functional Analysis using Gene Expression Microarray, Proteomics, and RNAi

**20.00 Gala dinner**

### **TUESDAY 18 September**

08.30 - 10.00 **Plenary P3 – Interferon induction and immune Response**

**Chair:** **Caetano Reis e Sousa /D.Tough**

08.30 – 09.00 **D. Tough**

09.00 – 09.15 P-3-1 **Burke D** IFN-mediated inactivation of the 4E-BP1 repressor of mRNA translation influences an antiviral response: 4E-BP1<sup>-/-</sup> mice are less susceptible to respiratory influenza infection.

09.15 – 09.30 P-3-2 **Watling D** ATM is Required for the Interferon-gamma Response

09.30 – 09.45 P-3-3 **Diamond M** Demonstration of Nonoverlapping Roles of Type I and Type II Interferons in Cancer Immunosurveillance

09.45 – 10.00 P-3-4 **Gerlach N** Anti-retroviral effects of type I interferon subtypes in vivo

10.30 - 11.00 **Coffee break**

11.00 - 13.00      **Break-out sessions:**

**B5 - Novel interferons and new developments**

Chair:              **S Pellegrini/J Symons**

- 11.00 – 11.30      **J. Symons** Novel Interferons – towards a modified super interferon.
- 11.30 – 11.45      B-5-1 **Donnelly R** Interferon-Lambda Is A Potent Inducer Of Type I IFN-Stimulated Genes In Primary Hepatocytes
- 11.45 – 12.00      B-5-2 **Eisele B** Soluferon® - a 2nd generation interferon-β with increased bioavailability
- 12.00 – 12.15      B-5-3 **Kotenko S** IFN-λs are Important Mediators of Antiviral Protection in Epithelial Cells
- 12.15 – 12.30      B-5-4 **Michiels T** IFN-I versus IFN-III: Tissue-Specificity of Expression and Response
- 12.30 – 12.45      B-5-5 **Subramanian M** Albinterferon α-2b (alb-IFN): Anti-HCV Activity and Pharmacokinetics/Pharmacodynamics
- 12.45 – 13.00      B-5-6 **Thomson S** Role for IFN-αs in rheumatoid arthritis

**B6 – Interferons and cancer**

Chair:              **J Kirkwood/E Borden**

- 11.00 – 11.30      **E Borden** Interferons for cancer: at middle age (B-6-1)
- 11.30 – 11.45      B-6-2 **Fleischman** Differential Induction Of IL-15 mRNA and IL-15 Protein Correlates With Cancer Vaccine Efficacy
- 11.45 – 12.00      B-6-3 **Morrison B** Somatic mutations of inositol hexakisphosphate kinase 2 in tumors of head and neck squamous cell carcinoma patients
- 12.00 – 12.15      B-6-4 **Goubau D** Distinct roles for IRF-3 and IRF-7 in the activation of anti-tumor properties of primary human macrophages
- 12.15 – 12.30      B-6-5 **Dong B** An Infectious Retrovirus Susceptible to an Interferon Antiviral Pathway from Human Prostate Tumors
- 12.30 – 12.45      B-6-6 **Nallar SC** Tumor-suppressive Protein GRIM-19 Inhibits Src-induced Oncogenic Transformation at Multiple Levels

13.00 - 14.30      **LUNCH & POSTERS**

14.30 - 16.30      **Break-out Sessions:**

**B7 – Interferons and autoimmunity**

Chair:            **A. Meager/C Biron**

- 14.30 – 15.00      **C Biron** Interferon and autoimmunity
- 15.00 – 15.15      B-7-1 **Coccia E** IFN-beta impairs plasmacytoid dendritic cell maturation: a novel target for IFN- beta therapy in Multiple Sclerosis
- 15.15 – 15.30      B-7-2 **Prinz M** Engagement Of Ifnar On Myeloid Cells Determines The Course Of Autoimmunity In The Central Nervous System
- 15.30 – 15.45      B-7-3 **Blanco J** Induction of type I interferons and Interferon-inducible Mx genes during Respiratory Syncytial Virus (RSV) infection and re-infection in cotton rats
- 15.45 – 16.00      B-7-4 **Mondini M** A Novel Role of the Interferon-Inducible Protein IFI16 as Inducer of Proinflammatory Molecules in Endothelial Cells
- 16.00 – 16.15      B-7-5 **Rahimi A** PI3K and P38 MAPK Differentially Regulate Expression of IL-12 Family Cytokines (IL-23 and IL-27) in LPS-induced Human Monocytic Cells
- 16.15 – 16.30      B-7-6 **Hoshino T** A role for IL-18 and IL-13 in the induction and progression of pulmonary inflammation and emphysema

**B8 - Inhibitors of interferons**

Chair:            **P Hertzog/A.Alcami**

- 14.30 – 15.00      **P. Hertzog** Non viral inhibitors of interferon
- 15.00 – 15-30      **A Alcami** Viral inhibitors of interferon
- 15.30 – 15.45      B-8-1 **Dixon L** The African swine fever virus DP71L virulence factor inhibts induction of type I interferon
- 15.45 – 16.00      B-8-2 **Jia D** Expression of avian influenza A H5N1 non-structural protein 1(NS1) alters type I IFN mediated signaling
- 16.00 – 16.15      B-8-3 **Walter M** Crystal Structure and Functional Analysis of the Ectromelia Virus Interferon- $\gamma$  Binding Protein
- 16.15 – 16.30      B-8-4 **Sobrido L** Inhibition of interferon induction by the nucleoprotein (NP) proteins of Arenaviruses
- 16.30 -17.00      **Tea break**

17.00 - 19.15            **Plenary P4 - Clinical roles of interferons - antiviral and MS**

Chair:            **S. Zeuzem/R.Ransohof**

17.00 – 17.30 **S. Zeuzem** Interferon and viral hepatitis

17.30 – 18.00 **R.Ransohoff** Interferon in multiple sclerosis

18.00 – 18.15            P-4-1 **Dianzani F** Possible Use of IFN to Prevent HIV-1 Rebound After HAART Interruption

18.15 – 18.30            P-4-2 **Van Weyenbergh** A polymorphism in a STAT1 binding site of the FAS promoter determines IFN-alpha-induced apoptosis in vitro and survival in Adult T-cell Leukemia

18.30 – 18.45            P-4-3 **Drittanti L** Belerofon<sup>®</sup>: a long-lasting and orally available single-amino acid mutant of Interferon alpha

18.45 – 19.00            P-4-4 **Baron S** Innate Immunity: Preclinical Study of Conditions Required for Eradication of Tumor Cells by Activated Monocytes in Vitro and in Vivo

19.00 – 19.15            P-4-5 **Gamal E** A Novel PEG-IFN- $\alpha$ 2a in Chronic HCV Genotype 4 Patients

**WEDNESDAY 19 September**

08.30 - 10.45            **Plenary P5 - Antiviral effects of the interferons**

Chair:            **O Haller/ R. Silverman**

08.30 – 09.00 **R. Silverman** Viral Encounters with RNASE-L during antiviral innate immunity(P-5-1)

09.00 - 09.30 **O Haller** Highly pathogenic influenza viruses: Mx restriction and escape(P-5-6)

09.30 – 09.45            P-5-2 **Chen H-M** Role of interferon regulatory factor 5 (IRF5) transcription factor in antiviral immunity and tumor suppression

09.45 – 10.00            P-5-3 **Erickson A** A recombinant human OAS1 has potent antiviral effects against the Hepatitis C Virus

10.00 – 10.15            P-5-4 **Fish E** IFN Mimetics As Broad Spectrum Antivirals

10.15 – 10.30            P-5-5 **Francois C** Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity

10.30 – 10.45            P-5-7 **Klimstra W** A PKR-Independent Interferon-Induced Antiviral Activity That Inhibits Translation Of mRNA Introduced Into The Cell Cytoplasm

10.30 - 11.00           **Tea Break**

11.00 - 13.00           **Plenary P6 – Life, Death and Growth Control**

Chair:               **A.Kimchi/J Darnell**

11.00 – 11.30 **A. Kimchi** Cell growth control

11.30 – 12.00 **J. Darnell** Thoughts on STAT3 - Antiapoptosis and Inhibitors

12.00 – 12.15           P-6-1 **Cheriyath V** Histone deacetylase (HDAC) inhibition augments  
IFN- $\alpha$ 2b induced gene expression and antiproliferative effects in  
myeloma.

12.15 – 12.30           P-6-2 **Contente S** Role of Pro-Lysyl Oxidase in Interferon-Induced  
Reversion of *ras*-Transformed Cells

12.30 – 12.45           P-6-3 **Kalvakolanu D** A Novel Interferon-Retinoid Induced Tumor  
Suppressive Pathway

12.45 – 13.00           P-6-4 **Lundgren E** The differential ability of multisubtype and single  
subtype IFN- $\alpha$  to suppress resistance development in melanoma  
cell lines as an effect of senescence induction

**CLOSE OF CONFERENCE**